

# Global Parkinson's Disease Drugs Market 2018-2024

<https://marketpublishers.com/r/G772F60DB6DEN.html>

Date: September 2018

Pages: 110

Price: US\$ 3,250.00 (Single User License)

ID: G772F60DB6DEN

## Abstracts

Global Parkinson's Disease Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024

Overview: Parkinson's disease is one of the most prevalent neurodegenerative disorders, which progresses with age because of damaged dopaminergic cells in the brain. Bradykinesia, rigidity, postural instability, and tremors are the symptoms of the Parkinson's disease. Huge patient pool and rising rate of diagnosis are the significant factors driving the market growth. The Parkinson's Disease Foundation has stated that nearly 10 million people are suffering from this disorder globally. The highest frequency of this disorder is observed in developed countries, and in the US, almost 60,000 new cases are reported annually.

PD is an idiopathic disease for which the cause of the occurrence is still unknown, hence only symptomatic drugs are available in the market for the treatment. Furthermore, the disorder is diagnosed in the final stages when the majority of the cells that produce dopamine lose their functionality. This is demanding more innovative and novel drugs for the treatment.

Market Analysis: The "Global Parkinson's Disease Drugs Market" is estimated to witness a CAGR of 7.2% during the forecast period 2018–2024. The market is analyzed based on two segments – drug class and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America accounts for the largest share of the market, followed by Europe, Asia Pacific, and Rest of the World. More than 40% of the market is occupied by Europe, with Germany being the major contributor to the market growth.

**Drug Class Analysis:** Based on drug classes, the market is segmented into levodopa, MAO-B inhibitors, COMT inhibitors, dopamine agonists, anticholinergics, and others. Levodopa is the most attractive drug in the market owing to its highly effective treatment in controlling the motor symptoms throughout the stages of Parkinson's disease. Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa. This is the original drug indicated explicitly for dyskinesia, which is technologically advanced with the long-term use of levodopa.

**Key Players:** The major players in the market include Novartis, Roche, AbbVie, Teva Pharmaceutical, Pfizer, STADA Arzneimittel AG, GSK, Valeant, Merck & Co. Inc., and Amneal Pharmaceuticals Inc.

**Competitive Analysis:** New product launch and collaboration are the primary strategies being followed by the market players to maintain their leadership and strengthen the market position. In January 2015, Neuropore Therapies Inc. and UCB S.A. signed a commercialization agreement for NPT200-11. Recently, Impax Pharmaceuticals' RYTARY and AbbVie's DUOPA received the US FDA approval for the treatment of Parkinson's disease. Other strategies include business partnerships, mergers & acquisitions, and a multifaceted pipeline. Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa.

**Benefits:** The report provides complete details about the usage and adoption rate of Parkinson's disease drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

## Contents

### 1 INDUSTRY OUTLOOK

#### 1.1 Industry Overview

- 1.1.1 Global Driver for Pharmaceutical Demand:
- 1.1.2 Pharmaceutical spending region wise
- 1.1.3 R&D pipeline in pharmaceutical industry
- 1.1.4 Top pharma drugs by sales in 2017 (\$Million)

#### 1.2 Total Addressable Market

### 2 REPORT OUTLINE

#### 2.1 Report Scope

#### 2.2 Report Summary

#### 2.3 Research Methodology

#### 2.4 Report Assumptions

### 3 MARKET SNAPSHOT

#### 3.1 Market Definition – Infoholic Research

#### 3.2 Segmented Addressable Market (SAM)

#### 3.3 Trends of Parkinson Diseases Market

#### 3.4 Related Markets

- 3.4.1 Neurosurgical Devices
- 3.4.2 Neurointerventional Devices
- 3.4.3 Over the counter drugs (OTC)

### 4 MARKET OUTLINE

#### 4.1 Pipeline Products of Parkinson Diseases Drugs

#### 4.2 Market Segmentation

#### 4.3 Porter 5(Five) Forces

#### 4.4 PEST Analysis

### 5 MARKET CHARACTERISTICS

#### 5.1 Market Dynamics of Parkinson Diseases Market

- 5.1.1 Drivers

- 5.1.1.1 Increasing Aging Population
- 5.1.1.2 Increasing Prevalence of Parkinson Diseases
- 5.1.2 Opportunities
  - 5.1.2.1 Supportive initiatives from government and other organizations
  - 5.1.2.2 Exhaustive Pipeline and Increasing Clinical Trials
- 5.1.3 Restraints
  - 5.1.3.1 Expiry of patents for blockbuster drugs and availability of generic drugs
  - 5.1.3.2 Complex drug development process
- 5.1.4 DRO – Impact Analysis
- 5.1.5 Key Stakeholders

## **6 DRUG TYPE: MARKET SIZE AND ANALYSIS**

- 6.1 Overview
- 6.2 Levodopa
- 6.3 Dopamine agonists
- 6.4 MAO-B inhibitors
- 6.5 COMT Inhibitor
- 6.6 Anticholinergics
- 6.7 Others

## **7 REGIONS: MARKET SIZE AND ANALYSIS**

- 7.1 Overview
- 7.2 North America
  - 7.2.1 Overview
- 7.3 Europe
  - 7.3.1 Overview
- 7.4 APAC
  - 7.4.1 Overview
- 7.5 Rest of the World
  - 7.5.1 Overview

## **8 COMPETITIVE LANDSCAPE**

## **9 VENDOR PROFILES**

- 9.1 Novartis AG
  - 9.1.1 Overview

- 9.1.2 Business Unit
- 9.1.3 Geographic Presence
- 9.1.4 Business Focus
- 9.1.5 SWOT Analysis
- 9.1.6 Business Strategy
- 9.2 GlaxoSmithKline plc
  - 9.2.1 Overview
  - 9.2.2 Geographic Presence
  - 9.2.3 Business Focus
  - 9.2.4 SWOT Analysis
  - 9.2.5 Business Strategy
- 9.3 F.Hoffmann-La Roche Ltd.
  - 9.3.1 Overview
  - 9.3.2 Business Unit
  - 9.3.3 Geographic Presence
  - 9.3.4 Business Focus
  - 9.3.5 SWOT Analysis
  - 9.3.6 Business Strategy
- 9.4 AbbVie Inc.
  - 9.4.1 Overview
  - 9.4.2 Geographic Presence
  - 9.4.3 Business Focus
  - 9.4.4 SWOT Analysis
  - 9.4.5 Business Strategies
- 9.5 Merck & Co., Inc.
  - 9.5.1 Overview
  - 9.5.2 Business units
    - 9.5.1 Geographic Revenue
    - 9.5.2 Business focus
  - 9.5.3 SWOT analysis
  - 9.5.4 Business strategies
- 9.6 Teva Pharmaceutical Industries Ltd.
  - 9.6.1 Overview
  - 9.6.2 Business Unit
  - 9.6.3 Geographic Presence
  - 9.6.4 Business focus
  - 9.6.5 SWOT analysis
  - 9.6.6 Business Strategy
- 9.7 Valeant Pharmaceuticals International Inc.

- 9.7.1 Overview
- 9.7.2 Business Unit
- 9.7.3 Geographic Presence
- 9.7.4 Business Focus
- 9.7.5 SWOT Analysis
- 9.7.6 Business Strategy

## **10 COMPANIES TO WATCH FOR**

- 10.1 Boehringer Ingelheim GmbH
    - 10.1.1 Overview
    - 10.1.2 Highlights
  - 10.2 Amneal Pharmaceuticals, Inc.
    - 10.2.1 Overview
  - 10.3 Wockhardt
    - 10.3.1 Overview
    - 10.3.2 Highlights:
  - 10.4 STADA Arzneimittel AG
    - 10.4.1 Overview
    - 10.4.2 Highlights
  - 10.5 Pfizer Inc.
    - 10.5.1 Overview
    - 10.5.2 Highlights
  - 10.6 Sun Pharmaceuticals
    - 10.6.1 Overview
    - 10.6.2 Highlights
- Annexure
- Abbreviations

## Tables

### TABLES

TABLE 1 CLINICAL TRIALS OF NEUROINTERVENTIONAL DEVICES

TABLE 2 PARKINSON DISEASES DRUGS: PIPELINE PRODUCTS

TABLE 3 PATENT EXPIRATION OF PARKINSON DISEASE DRUGS

TABLE 4 PARKINSON DISEASES MARKET REVENUE BY DRUG TYPE, 2017–2024  
(\$MILLION)

TABLE 5 PARKINSON DISEASES MARKET REVENUE BY REGIONS, 2017–2024  
(\$MILLION)

TABLE 6 NOVARTIS AG: OFFERINGS

TABLE 7 NOVARTIS AG: RECENT DEVELOPMENTS

TABLE 8 GLAXOSMITHKLINE PLC: OFFERINGS

TABLE 9 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

TABLE 10 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS

TABLE 11 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS

TABLE 12 ABBVIE INC.: OFFERINGS

TABLE 13 ABBVIE INC: RECENT DEVELOPMENTS

TABLE 1 MERCK & CO: PRODUCT OFFERINGS

TABLE 2 MERCK & CO: RECENT DEVELOPMENTS

TABLE 3 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS

TABLE 4 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS

TABLE 5 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS

TABLE 6 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT  
DEVELOPMENTS

TABLE 7 BOEHRINGER INGELHEIM GMBH: OVERVIEW

TABLE 8 BOEHRINGER INGELHEIM: RECENT DEVELOPMENTS

TABLE 9 AMNEAL PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW

TABLE 10 AMNEAL PHARMACEUTICAL: RECENT DEVELOPMENTS

TABLE 11 WOCKHARDT.: OVERVIEW

TABLE 12 STADA ARZNEIMITTEL AG: OVERVIEW

TABLE 13 STADA ARZNEIMITTEL AG: RECENT DEVELOPMENTS

TABLE 14 PFIZER INC. OVERVIEW

TABLE 15 PFIZER INC.: RECENT DEVELOPMENTS

TABLE 16 SUN PHARMACEUTICALS: OVERVIEW

TABLE 17 SUN PHARMACEUTICALS: RECENT DEVELOPMENTS

### CHARTS

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016)

CHART 2 R&D INVESTMENT BY TOP 10 COMPANIES (\$BN)

CHART 3 RESEARCH METHODOLOGY OF GLOBAL PARKINSONS DISEASES MARKET

CHART 4 GLOBAL PARKINSON DISEASE MARKET REVENUE, 2017-2024 (\$MILLION)

CHART 5 SEGMENTATION OF GLOBAL PARKINSON DISEASES DRUGS MARKET

CHART 6 PORTER 5 FORCES OF PARKINSON DISEASES MARKET

CHART 7 PEST ANALYSIS OF PARKINSON DISEASES MARKET

CHART 8 MARKET DYNAMICS – DRO ANALYSIS

CHART 9 DRO – IMPACT ANALYSIS OF GLOBAL PARKINSON DISEASES MARKET

CHART 10 KEY STAKEHOLDERS

CHART 11 PARKINSON DISEASE MARKET BY DRUG TYPE, 2017 VS 2024 (%)

CHART 12 LEVADOPA DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

CHART 13 DOPAMINE AGONIST MARKET REVENUE, 2017-2024 (\$MILLION)

CHART 14 MAO-B MARKET REVENUE, 2017-2024 (\$MILLION)

CHART 15 COMT INHIBITORS MARKET REVENUE, 2017-2024 (\$MILLION)

CHART 16 ANTICHOLINERGICS MARKET REVENUE, 2017-2024 (\$MILLION)

CHART 17 OTHER DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

CHART 18 PARKINSON DISEASES MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)

CHART 19 PARKINSON DISEASES MARKET REVENUE IN THE NORTH AMERICA REGION, 2017–2023 (\$MILLION)

CHART 20 THE PREVALENCE RATE OF PD IN EUROPE

CHART 21 PARKINSON DISEASES MARKET REVENUE IN THE EUROPEAN REGION, 2017–2023 (\$MILLION)

CHART 22 PARKINSON DISEASES MARKET REVENUE IN THE APAC REGION, 2017-2024 (\$MILLION)

CHART 23 PARKINSON DISEASES MARKET REVENUE IN REST OF THE WORLD, 2017–2024 (\$MILLION)

CHART 24 NOVARTIS AG: OVERVIEW SNAPSHOT

CHART 25 NOVARTIS AG: BUSINESS UNITS

CHART 26 NOVARTIS AG: GEOGRAPHICAL PRESENCE

CHART 27 NOVARTIS AG: SWOT ANALYSIS

CHART 28 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT

CHART 29 GLAXOSMITHKLINE PLC: BUSINESS UNITS

CHART 30 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE

CHART 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS



CHART 32 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT  
CHART 33 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS  
CHART 34 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE  
CHART 35 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS  
CHART 36 ABBVIEE INC: OVERVIEW SNAPSHOT  
CHART 37 ABBVIEE INC.: GEOGRAPHIC PRESENCE  
CHART 38 ABBVIE INC.: SWOT ANALYSIS  
CHART 39 MERCK & CO: OVERVIEW SNAPSHOT  
CHART 40 MERCK & CO: BUSINESS UNITS  
CHART 41 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE  
CHART 42 MERCK & CO: SWOT ANALYSIS  
CHART 43 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT  
CHART 44 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS  
CHART 45 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE  
CHART 46 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS  
CHART 47 VALEANT PHARMACEUTICALS INTERNATIONAL INC: OVERVIEW SNAPSHOT  
CHART 48 VALEANT PHARMACEUTICALS INTERNATIONAL INC: BUSINESS UNITS  
CHART 49 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL PRESENCE  
CHART 50 VALEANT PHARMACEUTICALS INTERNATIONAL INC: SWOT ANALYSIS

## I would like to order

Product name: Global Parkinson's Disease Drugs Market 2018-2024

Product link: <https://marketpublishers.com/r/G772F60DB6DEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G772F60DB6DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970